Page results
-
Specialist teams at UCLH and UCL are at the forefront of research which could bring hope to people who have been robbed of their sense of smell and taste after suffering the long-term legacy of COVID-19.
-
The National Day Care Unit provides an opportunity for many people to receive different treatments, tests and procedures without having to stay overnight in the hospital. Some eligible patients who need more than one day of treatment will stay in a hotel near to the hospital.
-
Information on contrast agents for X-ray, fluoroscopy, CT and angiography examinations at NHNN
-
This page provides information on examinations using contrast agents in MRI. It is intended for use by patients (or their families or carers) who have been referred to our service for imaging requiring contrast agents.
-
This page explains what spasticity is. It contains information on botulinum toxin and its use to treat conditions such as spasticity and dystonia which can occur after a stroke or brain injury.
-
Patients with COVID-19 will be given the cystic fibrosis drug ‘Dornase alfa’ to determine if it can help improve survival by reducing excess inflammation in the lungs in a trial at UCLH.
-
Neurological complications of COVID-19 can include delirium, brain inflammation, stroke and nerve damage, finds a new UCL and UCLH-led study.
-
UCLH continues to achieve excellent results in the National Inpatient Survey. In 2021 patients rated their overall care as 8.5 out of 10 which is the top score in London and the second best in the Shelford Group.
-
UCLH will be part of a major UK research study looking at the long-term health impacts of COVID-19.
-
The Royal Parks Half Marathon makes a spectacular return this weekend.
File results
-
FOI/2023/0491 - Treatment for oesophageal and gastric cancer
-
FOI/2023/0493 - Treatments for various diseases
-
FOI/2023/0497 - List of all laboratories within Pathology
-
FOI/2023/0499 - Treatments for non-small cell lung cancer
-
FOI/2023/0500 - Treatment of urothelial and colorectal cancer
-
FOI/2023/0501 - Central Airway Tumour Management/ Endobronchial Valves for treatment of Emphysema
-
FOI/2023/0505 - Telecommunications infrastructure contract
-
FOI/2023/0507 - Mental health patient suicides
-
FOI/2023/0508 - Lynch syndrome clinical pathway
-
FOI/2023/0509 - Immunoglobulin treatments